Introduction
============

Lung cancer ranks second in incidence and first in mortality for both males and females, with an estimated 222,500 new cases and 155,870 deaths in 2017 ([@b1-ol-0-0-9174]). Unfortunately, the majority of lung cancer patients are diagnosed at an advanced stage and are typically not curable. The current gold standard for lung cancer diagnosis is pathological biopsy, which is an invasive method. With the development of nondestructive testing technology, novel non-invasive methods are needed to monitor and diagnose lung cancer. Though some findings regarding molecular mechanisms in lung cancer have been reported in recent years ([@b2-ol-0-0-9174]--[@b6-ol-0-0-9174]), the molecular regulatory mechanisms underlying the initiation and development of lung cancer remain unclear. Therefore, more studies are needed to explore the molecular mechanisms in lung cancer.

MicroRNAs (miRNAs) are highly conserved endogenous small non-coding RNAs approximately 23 nucleotides in length. They exert their effects through posttranscriptional repression in a sequence-specific manner ([@b7-ol-0-0-9174]). miRNAs have been found to perform crucial biological functions in the initiation and development of cancer ([@b8-ol-0-0-9174]). In addition, miRNAs have begun to be used for the diagnosis and treatment of cancer in recent years ([@b9-ol-0-0-9174]--[@b11-ol-0-0-9174]). The clinical significance of miRNA profiles in diagnosis and prognosis has also been evaluated in lung cancer ([@b12-ol-0-0-9174],[@b13-ol-0-0-9174]).

Over the past few years, miR-193a-5p has been found to be involved in multiple cancers, such as esophageal squamous cell carcinoma ([@b14-ol-0-0-9174]), bladder cancer ([@b15-ol-0-0-9174]), primary bone tumors ([@b16-ol-0-0-9174]), osteosarcoma ([@b17-ol-0-0-9174]), colorectal cancer ([@b18-ol-0-0-9174]) and endometrioid endometrial adenocarcinoma ([@b19-ol-0-0-9174]). Some noted pathways such as the PI3K/AKT signaling pathway, PTEN/AKT signaling pathway and mTOR signaling pathway have been implicated in the oncogenesis of different tumors and as therapeutic drug targets ([@b20-ol-0-0-9174]--[@b24-ol-0-0-9174]). Some studies have linked miR-193a-5p to lung cancer. For example, in Yu\'s study, miR-193a-5p was found to block the metastasis of non-small cell lung cancer by inhibiting the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway ([@b25-ol-0-0-9174]). Similarly, Chen *et al* ([@b26-ol-0-0-9174])revealed that the miR-193a-5p-WT1-E-cadherin axis plays a crucial role in the metastasis of non-small cell lung cancer. However, no study has reported the diagnostic value of miR-193a-5p in lung cancer.

Thus, we attempted to explore the clinical diagnostic significance of miR-193a-5p using a microarray meta-analysis. We also explored the possible molecular mechanisms using bioinformatics analysis. The results of this study could provide insights into the clinical diagnosis of lung cancer and guide future research on the underlying molecular mechanisms.

Materials and methods
=====================

### GEO dataset retrieval and data extraction

Lung cancer microarray data published through July 2017 were retrieved from the Gene Expression Omnibus (GEO) database. The retrieval strategies were as follows: (lung OR pulmonary OR respiratory OR bronchi OR bronchioles OR alveoli OR pneumocytes OR 'air way') and (cancer OR carcinoma OR tumor OR neoplas\* OR malignan\* OR adenocarcinoma) and (MicroRNA OR miRNA OR 'Micro RNA' OR 'Small Temporal RNA' OR 'non-coding RNA' OR ncRNA OR 'small RNA'). Microarray data meeting the following criteria were included: i) The subjects in the datasets included lung cancer patients and corresponding controls; ii) the expression profile of miR-193a-5p in both lung cancer patients and controls was available or calculable; and iii) the number of overall subjects was more than 30. The expression of miR-193a-5p was extracted from the included datasets and evaluated with means and standard deviations (SD) using SPSS 22.0 (SPSS, Inc., Chicago, IL, USA).

### Meta-analysis of the diagnostic value of miR-193a-5p in the GEO datasets

A meta-analysis of the included datasets was conducted to evaluate the diagnostic value of miR-193a-5p using Stata 12.0 software (StataCorp LP, College Station, TX, USA). The pooled effect was estimated as the standard mean difference (SMD) with a 95% confidence interval (CI). The heterogeneity was measured using a chi-squared test of Q and P values. I^2^\<50% or P\>0.05 indicated no significant heterogeneity. The publication bias of the datasets was assessed using Begg\'s funnel plots. A symmetrical funnel plot indicated no obvious publication bias. In addition, summary receiver operating characteristic (SROC) analysis was performed. The pooled diagnostic sensitivity, specificity, odds ratio (OR), positive likelihood ratio (LR) and negative LR were calculated to comprehensively evaluate the diagnostic value of miR-193a-5p.

### Identification of miR-193a-5p target genes

Possible target genes of miR-193a-5p were collected using miRWalk 2.0 (<http://zmf.umm.uni-heidelberg.de/mirwalk2>) ([@b27-ol-0-0-9174]), which combines 12 prediction databases. Genes predicted by at least 2 databases were selected. We also identified validated target genes of miR-193a-5p using the Tarbase and MitarBase databases. The predicted genes and validated genes were further compared to identify the most significant overlapping miR-193a-5p target genes.

### Exploration of the molecular mechanism of miR-193a-5p using bioinformatics analysis

The Database for Annotation, Visualization and Integrated Discovery (DAVID), an online bioinformatics functional enrichment tool for the analysis of large lists of genes ([@b28-ol-0-0-9174],[@b29-ol-0-0-9174]), was used to explore the enriched pathways of the overlapping genes. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed using the DAVID online functional annotation module. Furthermore, to identify hub genes, we used the STRING v10 database (<http://string-db.org/>) ([@b30-ol-0-0-9174]) to construct a protein-protein interaction (PPI) network. Genes with connection degrees higher than 3 were considered hub genes.

### Validation of hub gene expression using TCGA data

The Cancer Genome Atlas (TCGA) (<http://cancergenome.nih.gov>) database is one of the largest publicly funded project platforms, providing information regarding cancer-causing genome alterations for more than 30 cancer types ([@b31-ol-0-0-9174]). To validate the expression of the hub genes, we downloaded the RNA-sequencing data of lung cancer and non-cancerous tissues from the TCGA database. The hub gene expression data in lung cancer and non-cancerous tissues were extracted. The expression values were normalized by log2 transformation and imported into GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA). Unpaired Student\'s t-test and receiver operating characteristic (ROC) curve analyses were conducted to assess the expression differences and clinical significance. Scatter plots were constructed to visualize the differences in miR-193a-5p expression between lung cancer and non-cancerous tissues. In addition, the area under the curve (AUC) was calculated to evaluate the diagnostic capability of miR-193a-5p. A P-value \<0.05 was considered statistically significant.

### Validation of the protein expression of the hub genes

The Human Protein Atlas database (<https://www.proteinatlas.org/>) provides abundant proteome and transcriptome data for tissues, cells and cancers ([@b32-ol-0-0-9174]--[@b34-ol-0-0-9174]). The protein expression of the upregulated hub genes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) specimens was investigated using the Pathology Altas portal in The Human Protein Atlas database. Antibody staining was analyzed to reflect the protein expression, and only samples with a staining quality of over 75% were used. Pathological images of typical high/medium staining in LUSC cells were chosen for display in this study.

### Validation of the correlation analysis between miR-193a-5p and hub genes based on TCGA data

The expression data of miR-193a-5p and the six hub genes in lung cancer were downloaded from the TCGA database. The expression data of both miR-193a-5p and the hub genes were normalized by log2 transformation. Spearman\'s correlation analysis was further performed using GraphPad Prism 7.0 (GraphPad Software, Inc.). A Spearman correlation coefficient of r\<0 indicated a negative correlation between miR-193a-5p and its hub genes. P\<0.05 indicated the statistical significance of the correlation analysis.

Results
=======

### Overview of the included datasets

According to the retrieval criteria, a total of 15 datasets published from 2009 to 2016 were selected, including 7 peripheral blood datasets and 8 tissue datasets. The basic information of the included datasets is provided in [Table I](#tI-ol-0-0-9174){ref-type="table"} ([@b35-ol-0-0-9174]--[@b49-ol-0-0-9174]). In the 7 peripheral blood datasets, 453 lung cancer samples and 306 healthy controls were included. In the 8 tissue datasets, 693 lung cancer samples and 354 healthy controls were included. The miR-193a-5p expression data were normalized by log2 transformation and extracted as the mean and SD.

### Meta-analysis of the diagnostic value of peripheral blood miR-193a-5p

The expression of peripheral blood miR-193-5p in the 7 independent peripheral blood datasets was pooled in a forest plot ([Fig. 1A](#f1-ol-0-0-9174){ref-type="fig"}). The SMD was 0.29 (95% CI: 0.02 to 0.55; I^2^=56.0%; P=0.034). The SMD was pooled using a random-effects model since heterogeneity was observed (I^2^\>50% or P-value \<0.05). Publication bias was analyzed with a Begg\'s funnel plot ([Fig. 1B](#f1-ol-0-0-9174){ref-type="fig"}). The Begg\'s funnel plot was basically symmetrical, indicating that no significant publication bias existed among the 7 peripheral blood datasets. SROC analysis was carried out to further examine the diagnostic value of peripheral blood miR-193a-5p. As shown in [Fig. 2](#f2-ol-0-0-9174){ref-type="fig"}, the AUC was 0.67 with a 95% CI of 0.63 to 0.71. As shown in [Fig. 3A](#f3-ol-0-0-9174){ref-type="fig"}, the combined sensitivity was 0.74 (95% CI: 0.57 to 0.86; I^2^=84.56%; P=0.00), while the specificity was 0.56 (95% CI: 0.44 to 0.67; I^2^=68.08%; P=0.00). [Fig. 3B](#f3-ol-0-0-9174){ref-type="fig"} shows that the pooled diagnostic odds ratio (OR) was 3.21 (95% CI: 2.00 to 5.15). The pooled positive LR and negative LR were also calculated to evaluate the association between miR-193a-5p and lung cancer ([Fig. 4A and B](#f4-ol-0-0-9174){ref-type="fig"}). The pooled positive LR was 1.58 (95% CI: 1.35 to 1.85), while the negative LR was 0.57 (95% CI: 0.47 to 0.70).

### Meta-analysis of the diagnostic value of tissue miR-193-5p

As shown in [Fig. 5A](#f5-ol-0-0-9174){ref-type="fig"}, eight tissue datasets were pooled using a random-effects model, and the pooled SMD was −0.34 (95% CI: −0.59 to −0.08; I^2^=63.2%; P=0.008). A Begg\'s funnel plot was constructed, and no publication bias was found, as the funnel plot was symmetrical ([Fig. 5B](#f5-ol-0-0-9174){ref-type="fig"}). In addition, SROC curve analysis showed satisfactory diagnostic value of tissue miR-193-5p, with an AUC of 0.83 (95% CI: 0.79 to 0.86) ([Fig. 2B](#f2-ol-0-0-9174){ref-type="fig"}). The combined sensitivity and specificity was 0.65 (95% CI: 0.43--0.83) and 0.89 (95% CI: 0.58 to 0.98), respectively ([Fig. 6A](#f6-ol-0-0-9174){ref-type="fig"}). However, significant heterogeneity was found (I^2^\>50%; P\<0.05). The combined diagnostic OR was 5.08 (95% CI: 2.17 to 11.89), which was calculated using a random-effects model due to the heterogeneity ([Fig. 6B](#f6-ol-0-0-9174){ref-type="fig"}). Moreover, the pooled positive LR and negative LR was 2.15 (95% CI: 1.27 to 3.64) and 0.57 (95% CI: 0.42 to 0.77), respectively ([Fig. 7A and B](#f7-ol-0-0-9174){ref-type="fig"}).

### Identification of miR-193a-5p targets

A total of 12666 predicted target genes were obtained from miRWalk 2.0. Meanwhile, 94 validated target genes were collected from miRTarbase and Tarbase. Eighty-one overlapping genes were identified by comparing the predicted and validated target genes. The 81 overlapping genes are important miR-193a-5p target genes and were used for further bioinformatics analysis.

### Bioinformatics analysis of the overlapping genes

GO, KEGG and PPI bioinformatics analyses were carried out for the overlapping genes ([Table II](#tII-ol-0-0-9174){ref-type="table"}). As shown in [Fig. 8A](#f8-ol-0-0-9174){ref-type="fig"}, in biological process (BP), the top three enriched items were regulation of neuron apoptosis, negative regulation of kinase activity and skin development. In cellular component (CC), organelle outer membrane, mitochondrial outer membrane and fibrillar collagen were the top three enriched terms ([Fig. 8B](#f8-ol-0-0-9174){ref-type="fig"}). For molecular function (MF), the target genes were mainly enriched in tubulin-tyrosine ligase activity, protein dimerization activity and platelet-derived growth factor binding ([Fig. 8C](#f8-ol-0-0-9174){ref-type="fig"}). KEGG analysis showed that the significant terms associated with miR-193a-5p in lung cancer were pathway in cancer, prostate cancer and RIG-I-like receptor signaling pathway ([Fig. 8D](#f8-ol-0-0-9174){ref-type="fig"}). By constructing a PPI network ([Fig. 9](#f9-ol-0-0-9174){ref-type="fig"}), we identified 6 hub genes with a connection degree \>3 (ERBB2, NCBP2, COL1A1, PCSK9, CSNK2A1, and UBTF). These 6 hub genes were the most densely connected areas in the network and were supported by additional evidence based on known interactions. These genes were more likely to be functionally connected, thus showing great potential to be key target genes of miR-193a-5p in lung cancer.

### Hub gene expression validation and clinical significance

The expression of the six hub genes (ERBB2, NCBP2, COL1A1, PCSK9, CSNK2A1, UBTF) is shown in scatter plots. ROC curves were also generated. We found that the expression of five of the hub genes (ERBB2, NCBP2, COL1A1, CSNK2A1, UBTF) were significantly upregulated in cancer. In addition, ROC curve analysis also showed that NCBP2, COL1A1, CSNK2A1 had satisfactory diagnostic value ([Fig. 10](#f10-ol-0-0-9174){ref-type="fig"}). The AUC of ERBB2, NCBP2, COL1A1, CSNK2A1 and UBTF was 0.581, 0.898, 0.868, 0.899 and 0.723, respectively. However, the expression of PCSK9 was significantly downregulated in cancer, and the ROC curve analysis showed that its AUC was 0.899 ([Fig. 11](#f11-ol-0-0-9174){ref-type="fig"}).

### Protein expression of the upregulated hub genes

Antibody staining was performed ([Fig. 12](#f12-ol-0-0-9174){ref-type="fig"}) and among the five upregulated hub genes, ERBB2, NCBP2, COL1A1, CSNK2A1 and UBTF, we discovered that the antibody staining of NCBP2 and UBTF was high ([Fig. 12B and E](#f12-ol-0-0-9174){ref-type="fig"}), while that of ERBB2, COL1A1 and CSNK2A1 ([Fig. 12A, C and D](#f12-ol-0-0-9174){ref-type="fig"}) was moderate in pathological LUAD sections. In pathological LUSC sections, the antibody staining of NCBP2, CSNK2A1 and UBTF was high ([Fig. 12G, I and J](#f12-ol-0-0-9174){ref-type="fig"}), while that of ERBB2 and COL1A1 was moderate ([Fig. 12F and H](#f12-ol-0-0-9174){ref-type="fig"}). The protein expression of ERBB2, NCBP2, COL1A1, CSNK2A1 and UBTF was upregulated in both LUAD and LUSC pathological sections. ERBB2 and COL1A1 were localized in the cytoplasm and cell membrane in both LUAD and LUSC pathological sections. CSNK2A1 and UBTF staining was predominantly nuclear in both LUAD and LUSC pathological sections. In LUAD sections, NCBP2 staining was both cytoplasmic/membranous and nuclear, while in LUSC sections, it was observed only in the nucleus.

### Correlation between miR-193a-5p and hub genes

We analyzed a total of 1046 lung cancer samples from the TCGA database, including 533 LUAD and 513 LUSC samples. Among the five upregulated hub genes, we found that the expression of NCBP2 and CSNK2A1 was negatively correlated with that of miR-193a-5p (P\<0.05). The correlation coefficient r was −0.154 (CI: −0.214 to −0.092) and −0.156 (CI: −0.216 to −0.094), respectively ([Fig. 13](#f13-ol-0-0-9174){ref-type="fig"}). This finding further suggested that NCBP2 and CSNK2A1 are target genes of miR-193a-5p. However, there was no significant negative correlation between ERBB2, COL1A1 or UBTF and miR-193a-5p. Thus, based on our correlation analysis, we were unable to verify that ERBB2, COL1A1, and UBTF are miR-193a-5p target genes.

Discussion
==========

In this study, we aimed to examine the diagnostic value of peripheral blood and tissue miR-193a-5p expression. We also attempted to elucidate the molecular regulatory mechanism underlying miR-193a-5p in lung cancer. We selected eligible microarray datasets and conducted a meta-analysis to explore the clinical diagnostic significance of miR-193a-5p. We then used bioinformatics analysis to explore the potential molecular mechanism involved. We compared predicted and validated target genes of miR-193a-5p and identified the overlapping genes. GO, KEGG and PPI network analyses were further performed for the overlapping genes. This study therefore provides a foundation for future research on miR-193a-5p.

Over the past few decades, the identification of diagnostic biomarkers in lung cancer has been an important research focus. Some classic and useful biomarkers such as TP53 ([@b50-ol-0-0-9174],[@b51-ol-0-0-9174]), neuron-specific enolase (NSE) ([@b52-ol-0-0-9174],[@b53-ol-0-0-9174]), carcinoembryonic antigen (CEA) ([@b54-ol-0-0-9174],[@b55-ol-0-0-9174]), and the cytokeratin 19 fragment (CYFRA21-1) ([@b56-ol-0-0-9174],[@b57-ol-0-0-9174]) have been identified and applied in clinical diagnosis. Nevertheless, there is still a need to identify diagnostic markers of lung cancer. Increasingly, lncRNAs and miRNAs have been found to act as diagnostic markers in lung cancer ([@b58-ol-0-0-9174]--[@b62-ol-0-0-9174]). The combination of multiple diagnostic biomarkers would greatly improve the sensitivity and specificity of lung cancer diagnosis ([@b56-ol-0-0-9174],[@b63-ol-0-0-9174],[@b64-ol-0-0-9174]). Thus, each finding is likely to contribute to the future clinical diagnosis of lung cancer. No previous studies have elucidated the diagnostic value of miR-193a-5p through a comprehensive meta-analysis. In this study, we used a microarray meta-analysis to explore the diagnostic value of miR-193a-5p in lung cancer. We found that the expression of peripheral blood miR-193a-5p was significantly higher in lung cancer samples than in normal samples. The pooled AUC was 0.67, with a sensitivity of 0.74 and specificity of 0.56. The pooled diagnostic OR was 3.21, the positive likelihood ratio was 1.58 and the negative likelihood ratio was 0.57. Thus, peripheral blood miR-193a-5p displayed moderate diagnostic value. It may be useful to combine peripheral blood miR-193a-5p with other diagnostic markers to improve its clinical diagnostic efficacy. Surprisingly, in tissue samples, the expression of miR-193a-5p in lung cancer tissue was evidently reduced compared with normal tissue. The pooled AUC was 0.83, with a sensitivity of 0.65 and specificity of 0.89. The diagnostic OR was 5.08, the positive likelihood ratio was 2.15, and the negative likelihood ratio was 0.57. Thus, tissue miR-193a-5p expression exhibited satisfactory performance in diagnosing lung cancer and might be a promising clinical diagnostic biomarker. Interestingly, the expression of peripheral blood miR-193a-5p was not consistent with the expression observed in lung cancer tissue samples. The reasons for this discrepancy between peripheral blood and tissue miRNA expression remain unclear. The origin of peripheral blood miRNAs remains controversial. Some researchers have suggested that miRNAs are secreted through microvesicles/exosomes, and some miRNAs are expressed at a higher level in microvesicles than inside tumor cells ([@b65-ol-0-0-9174]--[@b67-ol-0-0-9174]). In another study, Pigati *et al* ([@b68-ol-0-0-9174]) found that miRNAs were selectively released from malignant cells and that the level of miRNAs released did not necessarily reflect the original abundance of miRNAs in cells. In Hu\'s study, it was suggested that the clinical role of serum miRNAs was independent from that in tissue samples ([@b69-ol-0-0-9174]). These findings may indicate why the expression profiles of miR-193a-5p were opposite in peripheral blood and tissue specimens in our study. Further studies are needed to determine the exact mechanism that causes the difference in expression. Still, peripheral blood and tissue miR-193a-5p could facilitate the diagnosis of lung cancer to some extent.

Since miR-193a-5p exerts its regulatory effects by specifically targeting certain genes, we identified potential miR-193a-5p target genes and further uncovered the underlying regulatory pathways. We found that the top enriched GO terms in BP, CC and MF were regulation of neuron apoptosis, organelle outer membrane and tubulin-tyrosine ligase activity, respectively. Mitochondria are important organelles in most eukaryotes. Mitochondrial outer membrane permeabilization has been reported to be involved in cancer and may be a promising therapeutic target ([@b70-ol-0-0-9174],[@b71-ol-0-0-9174]). Therefore, miR-193a-5p might also participate in lung cancer through a similar mechanism. Recently, widespread loss of tubulin tyrosine ligase has been found during tumor growth, suggesting that tubulin tyrosine ligase activity might be involved in the regulation of tumor cells ([@b72-ol-0-0-9174]). Tubulin tyrosine ligase activity may be associated with miR-193a-5p, which might exert effects in lung cancer. However, more studies are needed to confirm this. In our KEGG analysis, the terms pathways in cancer, prostate cancer and RIG-I-like receptor signaling pathway were determined to be important. However, no studies have yet determined the relationship between miR-193a-5p and these pathways. Thus, more studies are urgently required. Through PPI network construction, six hub genes were identified (ERBB2, NCBP2, COL1A1, PCSK9, CSNK2A1, UBTF). By analyzing TCGA data, we discovered that among the six hub genes, five (ERBB2, NCBP2, COL1A1, CSNK2A1, UBTF) were significantly upregulated in lung cancer tissue. Since the expression of miR-193a-5p in lung cancer tissue was downregulated, the five upregulated hub genes (ERBB2, NCBP2, COL1A1, CSNK2A1, UBTF) are likely to be target genes of miR-193a-5p in lung cancer. However, more studies are needed to investigate the relationship between the significantly downregulated hub gene, PCSK9, and miR-193a-5p in lung cancer. Interestingly, we further verified that the protein expression of ERBB2, NCBP2, COL1A1, CSNK2A1 and UBTF was also upregulated according to antibody staining in LUAD and LUSC pathological sections. These results further demonstrated the upregulation of ERBB2, NCBP2, COL1A1, CSNK2A1 and UBTF in lung cancer, indicating that they are likely to be targets of miR-193a-5p. Of the five upregulated hub genes, NCBP2 and CSNK2A1 were found to be negatively correlated with miR-193a-5p. Consequently, we focused on NCBP2 and CSNK2A1 in the detailed discussion below.

NCBP2 (nuclear cap binding protein subunit 2) is also known as CBC2. Its protein product is a component of the nuclear cap-binding protein complex. NCBP2 has been reported as a key target gene in ovarian carcinoma ([@b73-ol-0-0-9174]). However, we did not find any studies on NCBP2 and lung cancer. In our study, we found that the protein expression of NCBP2 was increased in both LUAD and LUSC samples. In addition, miR-193a-5p was found to be negatively correlated with NCBP2 (r=−0.154). These findings provided more evidence suggesting that NCBP2 may be a target of miR-193a-5p in lung cancer. Nevertheless, more relevant studies are required to further validate this hypothesis.

CSNK2A1 (casein kinase 2 alpha 1), also known as CKII, is a serine/threonine protein kinase that participates in various cellular processes, including the cell cycle, apoptosis, and circadian rhythm. Over the past few years, CSNK2A1 has been found to play a significant role in the survival of cancer patients, suggesting that it may be a promising therapeutic target ([@b74-ol-0-0-9174]--[@b76-ol-0-0-9174]). For example, in Bae JS\'s study, CSNK2A1 was found to participate in the progression of breast carcinoma and to indicate poorer patient survival ([@b77-ol-0-0-9174]). In addition, Rabjerg *et al* ([@b78-ol-0-0-9174]) identified CSNK2A1 as a promising novel prognostic biomarker in clear cell renal carcinoma. Furthermore, CSNK2A1 has also been found to be involved in ovarian cancer ([@b79-ol-0-0-9174]), oral cancer ([@b80-ol-0-0-9174]), prostate cancer ([@b81-ol-0-0-9174],[@b82-ol-0-0-9174]) and pancreatic cancer ([@b83-ol-0-0-9174]). A CK2 inhibitor has been implicated in the apoptosis, migration, and metastasis of lung cancer cells ([@b84-ol-0-0-9174]--[@b87-ol-0-0-9174]). Increased protein expression of CSNK2A1 was observed in both LUAD and LUSC samples. We also observed a negative correlation between miR-193a-5p and CSNK2A1 according to an analysis of TCGA data (r=−0.156). Thus, CSNK2A1 could be a promising therapeutic target in lung cancer. Still, further experimental studies are needed.

In conclusion, in this study we discovered that peripheral blood and tissue miR-193a-5p could be a promising diagnostic biomarker for the clinical diagnosis of lung cancer. Several pathways regulated by miR-193a-5p and its targets, including pathways in cancer, prostate cancer and the RIG-I-like receptor signaling pathway, might be important in lung cancer. In addition, six hub genes, ERBB2, COL1A1, PCSK9, UBTF, and particularly NCBP2 and CSNK2A1, were identified as key target genes of miR-193a-5p. However, there were some limitations in this study. The analysis was based on online databases, and we only performed bioinformatics analyses. More experiments are needed to validate the findings. Luciferase assays would be a powerful method to validate the findings in the current study. Clinicall, this study could offer possible insights into lung cancer diagnosis and provide a basis for future research on the molecular mechanisms involved.
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![Meta-analysis evaluating the diagnostic value of tissue miR-193a-5p. (A) Forest plot determining the differences in tissue miR-193a-5p. (B) Funnel plot determining the publication bias of the included tissue datasets. miR, microRNA; SMD, standard mean difference.](ol-16-04-4114-g04){#f5-ol-0-0-9174}

![Forest plots evaluating the diagnostic sensitivity, specificity and odds ratio (OR) of tissue miR-193a-5p. (A) Pooled sensitivity and specificity of tissue miR-193a-5p. (B) Pooled diagnostic OR of tissue miR-193a-5p. OR, odds ratio; miR, microRNA.](ol-16-04-4114-g05){#f6-ol-0-0-9174}

![Forest plots evaluating the pooled positive and negative likelihood ratios (LRs) of tissue miR-193a-5p. (A) Pooled positive LR of tissue miR-193a-5p. (B) Pooled negative LR tissue miR-193a-5p. LR, likelihood ratio; miR, microRNA.](ol-16-04-4114-g06){#f7-ol-0-0-9174}

###### 

Significantly enriched GO and KEGG terms for the 81 overlapping genes. The X-axis represents the number of genes, and the Y-axis represents different terms. (A) The significantly enriched BP terms. (B) The significantly enriched CC terms. (C) The significantly enriched molecular function (MF) terms. (D) The significantly enriched KEGG terms. BP, biological process; CC, cellular component. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cellular component; MF, molecular function.
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![Protein-protein interaction network of the overlapping genes. Each node represents a protein. Filled nodes indicate that 3D structure of the protein is known or predicted. Empty nodes indicate that the 3D structure of the protein has not been determined. The edges among the nodes represent the protein associations. The edge thickness indicates the confidence level. PPI, protein-protein interaction.](ol-16-04-4114-g09){#f9-ol-0-0-9174}

![The expression scatter plots and ROC curves of the five upregulated hub genes. (A) The expression of ERBB2 in lung cancer and normal tissues. (B) The ROC curve of ERBB2 to assess the diagnostic value. (C) The expression of NCBP2 in lung cancer and normal tissues. (D) The ROC curve of NCBP2 to assess the diagnostic value. (E) The expression of COL1A1 in lung cancer and normal tissues. (F) The ROC curve of COL1A1 to assess the diagnostic value. (G) The expression of CSKN2A1 in lung cancer and normal tissues. (H) The ROC curve of CSKN2A1 to assess the diagnostic value. (I) The expression of UBTF in lung cancer and normal tissues. (J) The ROC curve of UBTF in lung cancer and normal tissues. ROC, receiver operating characteristic; AUC, area under the curve.](ol-16-04-4114-g10){#f10-ol-0-0-9174}

![The expression scatter plots and ROC curve of the downregulated hub gene. (A) The expression of PCKS9 in lung cancer and normal tissues. (B) The ROC curve of PCKS9 in lung cancer and normal tissues. ROC, receiver operating characteristic; AUC, area under the curve.](ol-16-04-4114-g11){#f11-ol-0-0-9174}

![The protein expression of the hub genes based on The Human Protein Atlas database (<https://www.proteinatlas.org/>). Brown staining indicates protein expression. Darker staining indicates higher protein expression. (A) Medium staining of ERBB2 in LUAD (stained with the antibody HPA001383). (B) High staining of NCBP2 in LUAD (stained with the antibody HPA044850). (C) Medium staining of COL1A1 in LUAD (stained with the antibody HPA011795). (D) Medium staining of CSNK2A1 in LUAD (stained with the antibody CAB069395). (E) High staining of UBTF in LUAD (stained with the antibody CAB004611). (F) Medium staining of ERBB2 in LUSC (stained with the antibody HPA001383). (G) High staining of NCBP2 in LUSC (stained with the antibody HPA044850). (H) Medium staining of COL1A1 in LUSC (stained with the antibody HPA011795). (I) High staining of CSNK2A1 in LUSC (stained with the antibody CAB069395). (J) High staining of UBTF in LUSC (stained with the antibody CAB004611). Magnification, ×40. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.](ol-16-04-4114-g12){#f12-ol-0-0-9174}

![The correlation between miR-193a-5p and hub genes. Each plot represents a lung cancer sample. The X-axis represents the expression of miR-193a-5p. The Y-axis represents the expression of hub genes. (A) miR-193a-5p is negatively correlated with NCBP2. (B) miR-193a-5p is negatively correlated with CSNK2A1. miR, microRNA.](ol-16-04-4114-g13){#f13-ol-0-0-9174}

###### 

Characteristics of the GEO datasets included in the meta-analysis.

  Study information   Sample   Array and annotation information                                                        
  ------------------- -------- ---------------------------------- ------------------ ---------- ----- ----- ---------- ----------------------
  Keller *et al*      2009     Germany                            Peripheral blood   GSE17681   17    19    GPL9040    ([@b35-ol-0-0-9174])
  Patnaik *et al*     2011     USA                                Peripheral blood   GSE27486   22    32    GPL11432   ([@b36-ol-0-0-9174])
  Keller *et al*      2011     Germany                            Peripheral blood   GSE31568   32    67    GPL9040    ([@b37-ol-0-0-9174])
  Patnaik *et al*     2012     USA                                Peripheral blood   GSE40738   82    58    GPL16016   ([@b38-ol-0-0-9174])
  Keller *et al*      2014     Germany                            Peripheral blood   GSE61741   73    94    GPL9040    ([@b39-ol-0-0-9174])
  Godrey *et al*      2014     USA                                Peripheral blood   GSE46729   24    24    GPL8786    ([@b40-ol-0-0-9174])
  Leidinger *et al*   2015     Germany                            Peripheral blood   GSE68951   203   12    GPL16770   ([@b41-ol-0-0-9174])
  Tan *et al*         2010     China                              SCLC/NSCLC         GSE15008   182   185   GPL8176    ([@b42-ol-0-0-9174])
  Nymark *et al*      2011     Finland                            NSCLC              GSE25508   26    26    GPL7731    ([@b43-ol-0-0-9174])
  Ohba *et al*        2013     Japan                              NSCLC/SCLC         GSE19945   55    8     GPL9948    ([@b44-ol-0-0-9174])
  Bjaanaes *et al*    2014     Norway                             LUAD               GSE48414   154   20    GPL16770   ([@b45-ol-0-0-9174])
  Robles *et al*      2015     USA                                LUAD               GSE63805   32    30    GPL18410   ([@b46-ol-0-0-9174])
  Gasparini *et al*   2015     Switzerland                        NSCLC              GSE72526   67    18    GPL20275   ([@b47-ol-0-0-9174])
  Jin *et al*         2015     China                              SCLC/LUAD/LUSC     GSE74190   92    44    GPL19622   ([@b48-ol-0-0-9174])
  Yoshimoto *et al*   2016     Japan                              SCLC/LUAD          GSE77380   85    23    GPL16770   ([@b49-ol-0-0-9174])

NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

###### 

The significant GO and KEGG enriched terms of the 81 overlapping genes.

  Category        ID            Term                                             Count   P-value    Genes
  --------------- ------------- ------------------------------------------------ ------- ---------- ----------------------------------------------------------------------------------------------------------
  GOTERM_BP_FAT   GO:0043408    Regulation of MAPKKK cascade                     5       0.001553   FGF19, ERBB2, IGF2, TIMP2, TP73
  GOTERM_BP_FAT   GO:0001889    Liver development                                4       0.001824   CEBPA, ERBB2, CEBPG, PCSK9
  GOTERM_BP_FAT   GO:0045765    Regulation of angiogenesis                       4       0.002994   ERBB2, RNH1, ERAP1, RUNX1
  GOTERM_BP_FAT   GO:0044092    Negative regulation of molecular function        7       0.004164   CEBPG, RGS4, PCSK9, IGF2, TP73, DHCR24, THY1
  GOTERM_BP_FAT   GO:0010627    Regulation of protein kinase cascade             6       0.005595   MAVS, FGF19, ERBB2, IGF2, TIMP2, TP73
  GOTERM_BP_FAT   GO:0007243    Protein kinase cascade                           7       0.006808   ERBB2, RGS4, WNK1, DUSP10, MKNK2, IGF2, TANK
  GOTERM_BP_FAT   GO:0006469    Negative regulation of protein kinase activity   4       0.007393   RGS4, IGF2, TP73, THY1
  GOTERM_BP_FAT   GO:0043588    Skin development                                 3       0.007749   COL1A2, COL1A1, DHCR24
  GOTERM_BP_FAT   GO:0033673    Negative regulation of kinase activity           4       0.008115   RGS4, IGF2, TP73, THY1
  GOTERM_BP_FAT   GO:0043523    Regulation of neuron apoptosis                   4       0.008115   CASP9, PCSK9, TP73, DHCR24
  GOTERM_CC_FAT   GO:0005584    Collagen type I                                  2       0.008743   COL1A2, COL1A1
  GOTERM_CC_FAT   GO:0070013    Intracellular organelle lumen                    15      0.018944   CEBPA, NCBP2, PDCD11, CEBPG, TRIM25, IGF2, SENP5, RBBP6, CSNK2A1, UBTF, VCP, INTS4, ANXA11, CDK12, ERAP1
  GOTERM_CC_FAT   GO:0031981    Nuclear lumen                                    13      0.021220   NCBP2, CEBPA, PDCD11, CSNK2A1, UBTF, VCP, INTS4, CEBPG, ANXA11, CDK12, TRIM25, SENP5, RBBP6
  GOTERM_CC_FAT   GO:0005783    Endoplasmic reticulum                            10      0.022714   GABARAPL1, CYP1B1, VCP, ACO1, NUP210, PCSK9, ERAP1, IGF2, DHCR24, THY1
  GOTERM_CC_FAT   GO:0044421    Extracellular region part                        10      0.022714   HDGF, COL1A2, RNH1, PCSK9, IGF2, FSTL1, COL1A1, NRG1, TNFSF9, TIMP2
  GOTERM_CC_FAT   GO:0043233    Organelle lumen                                  15      0.022719   CEBPA, NCBP2, PDCD11, CEBPG, TRIM25, IGF2, SENP5, RBBP6, CSNK2A1, UBTF, VCP, INTS4, ANXA11, CDK12, ERAP1
  GOTERM_CC_FAT   GO:0031974    Membrane-enclosed lumen                          15      0.026486   CEBPA, NCBP2, PDCD11, CEBPG, TRIM25, IGF2, SENP5, RBBP6, CSNK2A1, UBTF, VCP, INTS4, ANXA11, CDK12, ERAP1
  GOTERM_CC_FAT   GO:0005583    Fibrillar collagen                               2       0.051347   COL1A2, COL1A1
  GOTERM_CC_FAT   GO:0005741    Mitochondrial outer membrane                     3       0.059102   MAVS, TOMM70A, BCL2L11
  GOTERM_CC_FAT   GO:0031968    Organelle outer membrane                         3       0.076066   MAVS, TOMM70A, BCL2L11
  GOTERM_MF_FAT   GO:0008047    Enzyme activator activity                        7       0.006987   CASP9, RGS4, RANBP1, MYO9B, NRG1, TIMP2, THY1
  GOTERM_MF_FAT   GO:0042802    Identical protein binding                        9       0.015402   CEBPA, ERBB2, COL1A2, CLDN1, PCSK9, TPRG1 L, MYO9B, COL1A1, RUNX1
  GOTERM_MF_FAT   GO:0019838    Growth factor binding                            4       0.016275   ERBB2, COL1A2, IGF2, COL1A1
  GOTERM_MF_FAT   GO:0043125    ErbB-3 class receptor binding                    2       0.020182   ERBB2, NRG1
  GOTERM_MF_FAT   GO:0000339    RNA cap binding                                  2       0.039963   NCBP2, EIF4G3
  GOTERM_MF_FAT   GO:0008083    Growth factor activity                           4       0.048576   FGF19, HDGF, IGF2, NRG1
  GOTERM_MF_FAT   GO:0048407    Platelet-derived growth factor binding           2       0.054540   COL1A2, COL1A1
  GOTERM_MF_FAT   GO:0046983    Protein dimerization activity                    7       0.056783   CEBPA, ERBB2, NUP210, CEBPG, NFE2L1, MYO9B, RUNX1
  GOTERM_MF_FAT   GO:0,004835   Tubulin-tyrosine ligase activity                 2       0.068899   TTLL4, TTLL11
  KEGG_PATHWAY    hsa04622      RIG-I-like receptor signaling pathway            3       0.053910   MAVS, TRIM25, TANK
  KEGG_PATHWAY    hsa05215      Prostate cancer                                  3       0.080182   CASP9, ERBB2, IGF2
  KEGG_PATHWAY    hsa05200      Pathways in cancer                               5       0.092374   FGF19, CEBPA, CASP9, ERBB2, RUNX1

GO, Gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
